Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb541 in Advanced Solid Tumors
NCT06276491Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of XmAb541 in ovarian cancer, endometrial cancer (EC) and germ cell tumor (GCT), sponsored by Xencor. Primary endpoints: Incidence of adverse events at 2 years, Incidence of dose-limiting toxicities at 28 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
XmAb541
03
Conditions
ovarian cancerendometrial cancer (EC)germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT06276491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276491.